CRIS Current Research Information System

TOSI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.790
AS - Asia 2.803
EU - Europa 2.558
AF - Africa 210
SA - Sud America 170
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.758
CN - Cina 798
SG - Singapore 758
GB - Regno Unito 712
VN - Vietnam 666
DE - Germania 363
SE - Svezia 349
IT - Italia 312
FR - Francia 172
UA - Ucraina 157
HK - Hong Kong 151
IN - India 144
BR - Brasile 123
RU - Federazione Russa 110
NL - Olanda 92
IE - Irlanda 89
ZA - Sudafrica 60
JP - Giappone 58
TG - Togo 56
EE - Estonia 48
CI - Costa d'Avorio 45
KR - Corea 40
FI - Finlandia 36
JO - Giordania 30
CH - Svizzera 25
TR - Turchia 25
BG - Bulgaria 23
CA - Canada 21
AR - Argentina 19
SC - Seychelles 19
PH - Filippine 18
TH - Thailandia 18
ID - Indonesia 16
BE - Belgio 14
IR - Iran 13
AT - Austria 12
GR - Grecia 11
EC - Ecuador 10
AU - Australia 9
BD - Bangladesh 8
CO - Colombia 8
LB - Libano 8
NG - Nigeria 8
PK - Pakistan 7
PL - Polonia 7
TW - Taiwan 7
CL - Cile 6
EG - Egitto 6
IQ - Iraq 6
MX - Messico 6
PT - Portogallo 6
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
ES - Italia 4
MA - Marocco 4
NP - Nepal 4
UG - Uganda 4
UZ - Uzbekistan 4
KE - Kenya 3
MY - Malesia 3
RO - Romania 3
RS - Serbia 3
TN - Tunisia 3
BY - Bielorussia 2
DO - Repubblica Dominicana 2
HN - Honduras 2
IL - Israele 2
LT - Lituania 2
MV - Maldive 2
QA - Qatar 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PY - Paraguay 1
SI - Slovenia 1
TJ - Tagikistan 1
Totale 9.541
Salva come PNG Salva come JPEG
Città #
Southend 589
Singapore 524
Fairfield 448
Ashburn 402
Chandler 275
Woodbridge 249
Seattle 193
Wilmington 184
Houston 175
Cambridge 163
San Jose 145
Ann Arbor 143
Hong Kong 140
Beijing 132
Dong Ket 128
Princeton 127
Jacksonville 110
Ho Chi Minh City 109
Santa Clara 99
Hanoi 98
Dublin 89
Boardman 80
Hefei 76
Nanjing 63
Padova 57
Lomé 56
Bremen 55
Westminster 55
Lauterbourg 51
Tokyo 49
Abidjan 45
Los Angeles 39
Jinan 37
Berlin 35
New York 34
Helsinki 31
San Diego 31
Amman 30
Shenyang 30
Frankfurt am Main 27
Hebei 27
Buffalo 25
Saint Petersburg 24
Seoul 24
Sofia 23
Turin 23
Haiphong 21
Bologna 20
Changsha 20
Milan 20
Mülheim 20
Bern 19
Munich 19
Nanchang 19
São Paulo 19
Tianjin 18
Redondo Beach 16
Shanghai 16
Hangzhou 15
Mahé 15
Redwood City 15
Zhengzhou 15
Redmond 14
The Dalles 14
Brussels 13
Da Nang 13
Dallas 13
Guangzhou 13
Falkenstein 12
Verona 12
Amsterdam 11
Dearborn 11
Jiaxing 11
Kunming 11
Paris 11
Rome 11
Wuhan 11
Chicago 10
Haikou 10
Medford 10
Hải Dương 9
Jakarta 9
London 9
Norwalk 9
Orem 9
Phoenix 9
Bengaluru 8
Bradford 8
Andover 7
Ankara 7
Bangkok 7
Des Moines 7
Lanzhou 7
Ningbo 7
Olalla 7
San Venanzo 7
Taizhou 7
Yubileyny 7
Chengdu 6
Florence 6
Totale 6.199
Salva come PNG Salva come JPEG
Nome #
Consensus conference on the management of tumor lysis syndrome. 440
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 250
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 218
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 214
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 210
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 210
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 203
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 196
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 195
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 193
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 192
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 192
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 192
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 189
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 189
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 181
Thalidomide maintenance in multiple myeloma: certainties and controversies. 180
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 174
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 172
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 171
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. 171
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. 167
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. 166
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 165
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 156
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 156
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 155
Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the "Gruppo Ematologico Di Romagna" (GER) 153
Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. 152
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 152
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 151
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 151
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 151
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). 145
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. 145
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). 145
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. 144
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. 143
Primary plasma cell leukemia in the era of new drugs: has something changed? 143
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. 141
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. 137
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 133
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. 133
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. 131
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 131
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. 126
Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma. 119
Survival and years of life lost in different age cohorts of patients with multiple myeloma. 113
International uniform response criteria for multiple myeloma. 108
Totale 9.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.399
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.399
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021419 0 0 0 0 0 0 0 0 0 66 73 280
2021/20221.087 120 29 67 99 108 67 16 68 34 98 191 190
2022/20231.317 153 210 70 196 58 100 47 62 206 49 105 61
2023/2024322 15 46 19 28 31 62 20 18 6 27 33 17
2024/20251.180 31 192 96 75 172 77 87 57 27 119 35 212
2025/20262.282 217 212 222 216 315 166 195 119 482 138 0 0
Totale 9.688